Next, mesenchymal chondroprogenitor N1511 cells were stimulated with cartducin, and three major groups of mitogen-activated protein kinase MAPK pathways and the phosphatidyl-inositol 3-k
Trang 1proliferation through both extracellular signal-regulated
Hironori Akiyama1,2, Souhei Furukawa2, Satoshi Wakisaka1and Takashi Maeda1
1 Department of Anatomy and Cell Biology, Graduate School of Dentistry, Osaka University, Japan
2 Department of Radiology, Graduate School of Dentistry, Osaka University, Japan
Cartilage formation is driven by mesenchymal
chon-droprogenitor cells that proliferate and differentiate
into chondrocytes The molecular mechanisms by
which growth factors regulate the fate of these cells
are not well defined We recently discovered a
secre-tory protein, cartducin, which is an 27 kDa
polypep-tide containing an N-terminal signal peppolypep-tide, a short
variable domain, a collagen-like domain, and a
C-ter-minal C1q-like globular domain Its mRNA is
predominantly and highly expressed in developing cartilages [1] Interestingly, cartducin has structural homology with a 30 kDa serum protein Acrp30⁄ adipo-nectin, which is exclusively and highly expressed in differentiated adipocytes [2], and has been shown to be dysregulated in various forms of obesity in mice and humans [3,4] Because cartducin is a paralog of Acrp30⁄ adiponectin, cartducin is a novel member of a newly designated C1q family of proteins [5,6] The
Keywords
cartducin; chondroprogenitor cells; MAPK;
PI3K ⁄ Akt; proliferation
Correspondence
T Maeda, Department of Anatomy and Cell
Biology, Graduate School of Dentistry,
Osaka University, 1–8 Yamadaoka, Suita,
Osaka 565–0871, Japan
Fax: +81 6 6879 2875
Tel: +81 6 6879 2874
E-mail: tmaeda@dent.osaka-u.ac.jp
(Received 20 November 2005, revised 20
February 2006, accepted 20 March 2006)
doi:10.1111/j.1742-4658.2006.05240.x
Cartducin, a paralog of Acrp30⁄ adiponectin, is a secretory protein pro-duced by both chondrogenic precursors and proliferating chondrocytes, and belongs to a novel C1q family of proteins We have recently shown that cartducin promotes the growth of both mesenchymal chondroprogeni-tor cells and chondrosarcoma-derived chondrocytic cells in vitro However, the cartducin-signaling pathways responsible for the regulation of cell pro-liferation have not been documented In this study, we examined whether cartducin exists in serum and further investigated the intracellular signaling pathways stimulated by cartducin in mesenchymal chondroprogenitor cells Western blot analysis showed that, unlike Acrp30⁄ adiponectin, cartducin was undetectable in mouse serum Next, mesenchymal chondroprogenitor N1511 cells were stimulated with cartducin, and three major groups of mitogen-activated protein kinase (MAPK) pathways and the phosphatidyl-inositol 3-kinase (PI3K)⁄ Akt signaling pathway were examined Cartducin activated extracellular signal-regulated kinase 1⁄ 2 (ERK1 ⁄ 2) and Akt, but not c-jun N-terminal kinase (JNK) nor p38 MAPK The MEK1⁄ 2 inhib-itor, U0126, blocked cartducin-stimulated ERK1⁄ 2 phosphorylation and suppressed the DNA synthesis induced by cartducin in N1511 cells The PI3K inhibitor, LY294002, blocked cartducin-stimulated Akt phosphoryla-tion and a decrease in cartducin-induced DNA synthesis in N1511 cells was also observed These data suggest that cartducin is a peripheral skeletal growth factor, and that the proliferation of mesenchymal chondroprogeni-tor cells stimulated by cartducin is associated with activations of the ERK1⁄ 2 and PI3K ⁄ Akt signaling pathways
Abbreviations
BrdU, bromodeoxyuridine; ERK, extracellular signal-regulated kinase; JNK, c-jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK ⁄ ERK kinase; a-MEM, alpha-minimal essential medium; PI3K, phosphatidylinositol 3-kinase.
Trang 2members of this family contain a C-terminal C1q-like
globular domain and are involved in processes as
diverse as host defense, inflammation, apoptosis,
auto-immunity, cell differentiation, organogenesis,
hiberna-tion and insulin-resistant obesity
More recently, we found that cartducin is strongly
expressed in both the chondrogenic cell lineage in
the sclerotome and proliferating chondrocytes in the
growth plate of cartilage, and it promotes the
prolifer-ation of mesenchymal chondroprogenitor cells and
chondrocytes in vitro [7] Although cartducin is a
bio-logically active molecule involved in both embryonic
cartilage development and postnatal longitudinal bone
growth, the signaling pathways activated upon
cartdu-cin stimulation have not been documented Because a
high mitogenic activity of mesenchymal
chondropro-genitor cells is initially required to produce enough
cells for the process of chondrogenesis [8], elucidation
of the signaling pathways responsible for
cartducin-induced DNA synthesis by mesenchymal
chondropro-genitor cells is necessary to more fully understand the
molecular mechanisms of cartilage formation
Mitogen-activated protein kinase (MAPK) pathways
are essential mitogenic pathways in many cell lines and
are responsible for various growth factors
Down-stream of these pathways can simply be classified into
three major groups mediated by the following kinases:
extracellular signal-regulated kinase (ERK), c-Jun
N-terminal kinase (JNK), and p38 MAPK [9,10]
Another signaling pathway associated with the control
of mitogenesis is the phosphatidylinositol 3-kinase
(PI3K)⁄ Akt pathway It is also an important mediator
of cell growth and survival in response to growth
factors and other signals PI3K activates Akt serine⁄
threonine kinase by generating specific inositol
phos-pholipids, which recruit Akt to the cell membrane and
enable its activation [11] In this study, we examined the
possibility that cartducin is a serum protein and further
investigated the possible signaling pathways activated
by cartducin in the regulation of DNA synthesis using
the mouse mesenchymal chondroprogenitor cell line,
N1511 [12] The results show that cartducin, a local
reg-ulatory factor, exerts its effects on the proliferation of
mesenchymal chondroprogenitor cells by activating
both the ERK1⁄ 2 and PI3K ⁄ Akt pathways
Results
Cartducin is a local regulatory factor but not a
systemic hormone
Cartducin is a novel growth factor which belongs to
a newly designated family of proteins, the C1q⁄ TNF
superfamily, all of which contain a C-terminal C1q-like globular domain and most of which contain a colla-genous region Based on the structural similarities of cartducin to the Acrp30⁄ adiponectin, which has been shown to play important roles in the regulation of glu-cose and lipid metabolism as a hormone, we investi-gated the possibility that cartducin is also a serum protein A protein of identical molecular mass to cart-ducin can be detected in the total tissue protein extrac-ted from mouse growth plate cartilage In contrast, unlike Acrp30⁄ adiponectin, we failed to detect cartdu-cin in mouse serum using western blot analysis (Fig 1) These results suggest that cartducin exerts its effects in vivo in an autocrine⁄ paracrine manner
Cartducin activates the ERK1⁄ 2 pathway in mesenchymal chondroprogenitor N1511 cells Cartducin is known to play important roles in regula-ting both chondrogenesis and cartilage development by its direct stimulatory action on the proliferation of chondrogenic precursors and chondrocytes MAPK pathways are essential mitogenic pathways in many cells and are responsible for various growth factors Three major groups of MAPKs, such as ERK, JNK, and p38 MAPK, have been identified Therefore, we analyzed the effects of cartducin on the phosphoryla-tion of these three groups of MAPKs in N1511 cells Western blot analysis showed that increased ERK1⁄ 2 phosphorylation in N1511 cells treated with
10 lgÆmL)1of cartducin was detected after 5 min, with maximal increase occurring after 15 min of treatment and decreasing after 1 h (Fig 2A) A dose-dependent increase in ERK1⁄ 2 phosphorylation in N1511 cells after 30 min of treatment was detected at 2, 5, and
10 lgÆmL)1of cartducin (Fig 2B) In contrast, cartdu-cin had no effect on the activities of JNK1⁄ 2 and p38
37
25
Cartducin
kDa
Car tila ge Seru m
Fig 1 Cartducin is not a serum protein One microliter of mouse serum was boiled for 5 min in 2 · sample buffer and analyzed by SDS ⁄ PAGE and western blot using anti-mouse IgG Antibody was visualized with an anti-goat IgG coupled to alkaline phosphatase.
A protein of identical molecular mass to cartducin can be detected
in the total tissue protein extracted from mouse growth plate carti-lage However, cartducin could not be detected in serum from mice.
Trang 3MAPK, and none of their phosphorylated forms was
detected (Fig 3) Both ERK1 and ERK2 have been
shown to be activated by their upstream activators,
MEK1 and MEK2 We next examined the action of
the specific MEK1⁄ 2 inhibitor, U0126, on ERK1 ⁄ 2
pathway activation Phosphorylation of ERK1⁄ 2
induced by cartducin was completely inhibited by
pre-treatment with U0126 (10 lm) (Fig 4)
ERK1⁄ 2 pathway activation is involved in
cartducin-induced proliferation of mesenchymal
chondroprogenitor N1511 cells
Because western blot analysis confirmed
cartducin-induced ERK1⁄ 2 pathway activation in N1511 cells,
we next determined whether cartducin-induced mesen-chymal chondroprogenitor cell proliferation is medi-ated through activation of the ERK1⁄ 2 pathway N1511 cells were pretreated with the MEK1⁄ 2 inhib-itor U0126 (10 lm), JNK inhibinhib-itor SP600125 (20 lm),
or p38 MAPK inhibitor SB203580 (10 lm) for 1 h before and for the duration of the stimulation, and DNA synthesis analysis by estimating the incorpor-ation of bromodeoxyuridine (BrdU) was performed (Fig 5) Cartducin induced about a twofold increase
in DNA synthesis in N1511 cells compared with the buffer-treated control culture Treatment with U0126, SP600125, or SB203580 suppressed the basal level of DNA synthesis in N1511 cells compared with the dimethylsulfoxide-treated control culture, respectively
Fig 3 Effects of cartducin on phosphorylation of JNK and p38
MAPK in N1511 cells Mesenchymal chondroprogenitor N1511 cells
stimulated with cartducin (10 lgÆmL)1) for 5, 15, 30, and 60 min
were analyzed by western blot for phosphorylated JNK1 ⁄ 2
(p-JNK1 ⁄ 2), total JNK1 ⁄ 2, phosphorylated p38 MAPK (p-p38 MAPK),
and total p38 MAPK Cartducin had no effect on the
phosphoryla-tion of JNK1 ⁄ 2 and p38 MAPK, and none of their phosphorylated
forms were detected.
Cartducin: – + –
+
+ U0126:
ERK1/2 p-ERK1/2
Fig 4 Effects of MAPK inhibitor on phosphorylation of ERK in N1511 cells Mesenchymal chondroprogenitor N1511 cells were pretreated with MEK1 ⁄ 2 inhibitor, U0126 (10 l M ), for 1 h, stimula-ted with cartducin (10 lgÆmL)1) for 15 min, and then analyzed by western blot for phosphorylated ERK1 ⁄ 2 (p-ERK1 ⁄ 2) Treatment with U0126 inhibited cartducin-induced ERK1 ⁄ 2 phosphorylation.
A
B
Fig 2 Effects of cartducin on phosphorylation of ERK in
mesen-chymal chondroprogenitor N1511 cells (A) Subconfluent cultures of
N1511 cells stimulated with cartducin (10 lgÆmL)1) for 5, 15, 30,
and 60 min were analyzed by western blot for phosphorylated
ERK1 ⁄ 2 (p-ERK1 ⁄ 2) and total ERK1 ⁄ 2 Cartducin increased the
p-ERK1 ⁄ 2 level after 5 min incubation Peak activation of ERK1 ⁄ 2
occurred at 15 min (B) Cells were stimulated with increasing doses
of cartducin (2–10 lgÆmL)1) for 30 min Cartducin induced a
dose-dependent activation of ERK1 ⁄ 2.
Fig 5 Effects of MAPK inhibitors on DNA synthesis in mesenchy-mal chondroprogenitor N1511 cells Subconfluent cultures of N1511 cells were serum starved, preincubated with MEK1 ⁄ 2 inhib-itor U0126 (10 l M ), JNK inhibitor SP600125 (20 l M ), or p38 MAPK inhibitor SB203580 (10 l M ) for 1 h before cartducin treatment (8 lgÆmL)1), and bromodeoxyuridine (BrdU) incorporation was measured Data are represented as the mean ± SD of triplicate determinations P < 0.05 versus cartducin-untreated each control Similar results were obtained from two independent experiments.
Trang 4Inhibition of the ERK1⁄ 2 pathway by pretreatment
with U0126 led to a block of cartducin-induced N1511
cell proliferation By contrast, inhibition of JNK or
p38 MAPK pathways by SP600125 or SB203580 did
not affect cartducin-induced N1511 cell proliferation
Cartducin activates the PI3K⁄ Akt pathway
in N1511 cells
The PI3K⁄ Akt pathway is also an important mediator
of cell growth and survival in response to growth
factors and other signals We therefore analyzed the
effects of cartducin on activation of the PI3K⁄ Akt
pathway in mesenchymal chondroprogenitor N1511
cells Western blot analysis showed that increased
Akt phosphorylation in N1511 cells treated with 10
lgÆmL)1 of cartducin was detected after 5 min, with
maximal increase occurring after 30 min of treatment
and decreasing after 1 h (Fig 6A) A dose-dependent
increase in Akt phosphorylation in N1511 cells after
30 min of treatment was detected at 2, 5, and
10 lgÆmL)1 of cartducin (Fig 6B) Next, the action of
the specific PI3K inhibitor, LY294002, on Akt
phos-phorylation was examined Phosphos-phorylation of Akt
induced by cartducin was inhibited completely by
pre-treatment with LY294002 (25 lm) (Fig 6C)
PI3K⁄ Akt pathway activation is involved in
cartducin-induced proliferation of mesenchymal
chondroprogenitor N1511 cells
Because western blot analysis confirmed
cartducin-induced PI3K⁄ Akt pathway activation in N1511 cells,
we further determined whether cartducin-induced
mesenchymal chondroprogenitor cell proliferation is
mediated through activation of the PI3K⁄ Akt
path-way N1511 cells were pretreated with the PI3K
inhib-itor, LY294002 (1–25 lm), for 1 h before and for the
duration of the stimulation, and DNA synthesis
analy-sis was performed (Fig 7) Similar to treatments with
MAPK inhibitors, treatment with LY294002 also
sup-pressed the basal level of DNA synthesis in N1511
cells Inhibition of the PI3K⁄ Akt pathway by
pretreat-ment with LY294002 significantly reduced DNA
syn-thesis in N1511 cells in a dose-dependent manner after
cartducin stimulation, suggesting involvement of the
PI3K⁄ Akt pathway in the ability of cartducin to
sti-mulate proliferation of these cells
Discussion
Skeletal development requires the condensation of
multipotential mesenchymal cells to differentiate
A
B
C
Fig 6 Cartducin-induced Akt phosphorylation is dependent on PI3K activity (A) Time course of cartducin-induced phosphorylation of Akt
in N1511 mesenchymal chondroprogenitor cells The cells stimula-ted with cartducin (10 lgÆmL)1) for 5, 15, 30, and 60 min were ana-lyzed by western blot for phosphorylated Akt (p-Akt) and total Akt Cartducin increased the p-Akt level after 5 min incubation Peak acti-vation of Akt occurred at 30 min (B) Dose–response of cartducin-induced phosphorylation of Akt in N1511 cells The cells were stimulated with increasing doses of cartducin (2–10 lgÆmL)1) for
30 min Cartducin induced a dose-dependent activation of Akt (C) Effects of PI3K inhibitor on phosphorylation of Akt in N1511 cells Cells were pretreated with the PI3K inhibitor, LY294002 (25 l M ), for
1 h, stimulated with cartducin (10 lgÆmL)1) for 30 min, and then analyzed by western blot for phosphorylated Akt (p-Akt) Treatment with LY294002 inhibited cartducin-induced Akt phosphorylation.
Fig 7 Effects of PI3K inhibitors on DNA synthesis in mesenchymal chondroprogenitor N1511 cells Subconfluent cultures of N1511 cells were serum starved, preincubated with PI3K inhibitor, LY294002 (1–25 l M ), for 1 h before cartducin treatment (8 lgÆmL)1), and BrdU incorporation was measured Treatment of N1511 cells with LY294002 inhibited the cartducin-stimulated DNA synthesis in a concentration-dependent manner Data are represen-ted as the mean ± SD of triplicate determinations P < 0.05 versus cartducin-untreated control Similar results were obtained from two independent experiments.
Trang 5toward the various cell types One such process is
cartilage formation from undifferentiated
mesenchy-mal cells Discoveries of diffusible factors that act
on the chondrogenic cell lineage and⁄ or chondrocytes
have dramatically improved our understanding of
the molecular mechanisms of skeletal development
Cartducin is a recently described cartilage-derived
secretory protein [1], and it has been indicated to
play important roles in regulating both embryonic
cartilage development and postnatal longitudinal
bone growth by directly promoting the proliferation
of mesenchymal chondroprogenitor cells and
chond-rocytes [7] Because cartducin shares a similar
modu-lar organization to the serum protein Acrp30⁄
adiponectin, which has been shown to play
import-ant roles as a hormone in the regulation of glucose
and lipid metabolism, we considered the possibility
that cartducin might be not only a local regulatory
factor, but also a systemic hormone However, we
could not detect cartducin in 1 lL (Fig 1) or more
(data not shown) of mouse serum using western blot
analysis These data suggested that cartducin is not
a serum protein, and thus cartducin may exert its
stimulatory action on the proliferation of
chondro-genic precursors and chondrocytes in vivo in an
autocrine⁄ paracrine fashion only
The expression of cartducin starts in the
sclero-tome, which contains a chondrogenic cell lineage
during mouse embryogenesis Recombinant cartducin
induced DNA synthesis in mesenchymal
chondropro-genitor N1511 cells in a dose-dependent manner [7]
In contrast to Acrp30⁄ adiponectin [13], a
cartducin-specific receptor has not yet been identified and
cloned, and little is known about its signaling
path-ways To gain insight into the mechanisms by which
cartducin promotes proliferation of mesenchymal
chondroprogenitor cells, we evaluated the signaling
events MAPKs are well known to play an essential
role in controlling cell proliferation and
differentia-tion [9,10] Indeed, the ERK1⁄ 2 pathway is involved
in controlling mesenchymal chondroprogenitor cell
proliferation [14] In this study, we found that
cart-ducin induces activation of ERK1⁄ 2 in mesenchymal
chondroprogenitor N1511 cells but has no effect on
activation of JNK and p38 MAPK Next, we
investi-gated the effects of MAPK inhibitors on the
prolif-eration of cartducin-stimulated N1511 cells by
analyzing DNA synthesis Inhibition of the ERK1⁄ 2
signaling pathway by the specific MEK1⁄ 2
inhib-itor, U0126, but not the specific JNK inhibinhib-itor,
SP600125, nor the specific p38 MAPK inhibitor,
SB203580, blocked cartducin-stimulated proliferation
of N1511 cells The data suggest that the ERK1⁄ 2
pathway has an important role in the proliferation
of mesenchymal chondroprogenitor cells stimulated
by cartducin JNK or p38 MAPK pathways do not seem to be involved in the cartducin-stimulated pro-liferation of these cells
Another signaling pathway associated with the con-trol of cell proliferation is the PI3K⁄ Akt pathway It is also an important mediator of cell growth and survival
in response to growth factors and other signals PI3K activates Akt serine⁄ threonine kinase by generating specific inositol phospholipids, which recruit Akt to the cell membrane and enable its activation [11] Akt mediates cell survival and growth signals by phos-phorylating and inactivating proapoptic proteins [15] Moreover, growth retardation has been reported in knockout mice for Akt1 gene, which demonstrates that Akt is important for normal growth [16] In the pre-sent study, we also found that the PI3K⁄ Akt pathway was activated by cartducin stimulation, and inhibition
of this signaling pathway by a specific PI3K inhibitor, LY294002, blocked the cartducin-stimulated pro-liferation of N1511 cells The data suggest that the PI3K⁄ Akt pathway is also involved in cartducin-stimu-lated proliferation of mesenchymal chondroprogenitor cells
Our results indicated that cartducin initiates MAPK and PI3K signaling cascades in mesenchymal chondroprogenitor cells, leading to the phosphoryla-tion of ERK1⁄ 2 and Akt, respectively, and both pathways are required for the cells to complete pro-gression through the mitotic cycle This finding is consistent with the well-established roles of these signaling pathways in the propagation of mitogenic signals [9,15] Although Akt has been thought to play a major role, mainly in cell survival, recent data suggest that PI3K activation is required for the pro-gression of mitosis, promoting the entry of quiescent cells into the S phase, and the downstream phos-phorylation of Akt is in part responsible for the propagation of this signal [17] In particular, the mitogenic response to platelet-derived growth factor involves the sequential activation of the MAPK and PI3K pathways, and these different phases of ling are a general requirement in mitogenic signa-ling [18] The inhibition of the mitogenic response to cartducin by the specific PI3K inhibitor, LY294002,
is consistent with this role for PI3K in mitogenesis
In conclusion, we have demonstrated that cartdu-cin, a novel C1q family member, is a peripheral skel-etal growth factor, and mitogenic response to cartducin by mesenchymal chondroprogenitor cells requires the activation of both the ERK1⁄ 2 and PI3K⁄ Akt pathways
Trang 6Experimental procedures
Reagents
Mouse recombinant cartducin was prepared as described
[7] Anti-mouse cartducin (also called CORS26) serum was
purchased from R&D Systems (Minneapolis, MN)
Anti-(ERK1⁄ 2), anti-(JNK1 ⁄ 2), and anti-(p38 MAPK) sera were
purchased from Sigma-Aldrich (St Louis, MO)
Anti-(p-ERK1⁄ 2), (p-JNK1 ⁄ 2), (p-p38 MAPK),
anti-Akt, and anti-(p-Akt) sera were purchased from Cell
Signaling Technology, Inc (Beverly, MA) MEK1⁄ 2
bitor U0126, JNK inhibitor SP600125, p38 MAPK
inhi-bitor SB203580, and PI3K inhiinhi-bitor LY294002 were
purchased from Calbiochem (San Diego, CA)
Cell lines and cell culture
The mouse mesenchymal chondroprogenitor cell line
N1511 [12] was cultured in alpha-minimal essential
med-ium (a-MEM; Sigma-Aldrich) supplemented with 10%
fetal bovine serum (FBS; PAA Laboratories, Linz,
Aus-tria), 2 mm l-glutamine, and penicillin⁄ streptomycin at
37C in a humidified atmosphere containing 5% CO2
To investigate the effects of cartducin on the MAPK or
PI3K⁄ Akt signaling pathways, cells were seeded at a
den-sity of 1· 104
cells per well in 24-well plates and grown
for 48 h The cells were then washed and cultured for
24 h in the medium without serum Subsequently,
10 lgÆmL)1 of recombinant cartducin was added to the
medium for 5, 15, 30, and 60 min In another set of
experiments, cells were treated with an increasing doses
of recombinant cartducin (2–10 lgÆmL)1) for 30 min For
experiments with protein kinase inhibitors, cells were
pre-treated with specific inhibitors for 1 h prior to cartducin
treatment
Western blot analysis
Total cellular protein was prepared by lysing cells in
Cel-Lytic lysis buffer (Sigma-Aldrich) containing protease
inhibitor (Sigma-Aldrich) and phosphatase inhibitor
(Sigma-Aldrich) cocktails Total tissue protein was
extrac-ted from rib growth plate cartilage from 10-day-old mice
The proteins (20 lg) were separated by SDS⁄ PAGE (10%
polyacrylamide gel) and transferred to a poly(vinylidene
difluoride) membrane (Bio-Rad, Hercules, CA) as described
previously [19] Membranes were blocked for 30 min
at room temperature and then incubated with anti
p-(ERK1⁄ 2), anti-(p-JNK1⁄ 2), anti-(p-p38 MAPK), or
anti-(p-Akt) sera for 18 h at 4C In other cases, the
membranes were incubated with first antibodies for 1 h at
room temperature The detection of bound antibodies
was performed by the WesternBreeze Chromogenic
Detect-ion System (Invitrogen, Carlsbad, CA) using alkaline
phosphatase-conjugated donkey goat IgG, or anti-rabbit IgG serum (Promega, Madison WI)
Measurement of DNA synthesis
To determine the growth-stimulatory effect of cartducin on mesenchymal chondroprogenitor cells, a BrdU assay was performed as described previously [7] In brief, N1511 cells were seeded at a density of 1· 104cells per well in 96-well plates and grown for 24 h The cells were then washed and the medium was replaced with a-MEM containing 0.3% FBS for 24 h Subsequently, 8 lgÆmL)1 of recombinant cartducin was added to the medium, incubated for 24 h, and labeled with BrdU for the last 3 h of incubation To determine the effects of inhibitors on the cartducin-induced proliferation of N1511 cells, cells were treated with different inhibitors for 1 h before and for the duration of the stimu-lation with cartducin In the control experiments, 50 mm NaH2PO4(pH 8.0) containing 1 mm EDTA and⁄ or dimeth-ylsulfoxide was added to the culture
Statistical analysis
An unpaired Student’s t-test was used for statistical analysis
of the experiments Error bars represent SD, and P < 0.05 was taken as the level of significance
Acknowledgements
This work was supported by Grants-in-aid for
Scienti-fic Research (No 16791142) and the 21st Century Center of Excellence Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan
References
1 Maeda T, Abe M, Kurisu K, Jikko A & Furukawa S (2001) Molecular cloning and characterization of a novel gene, CORS26, encoding a putative secretory pro-tein and its possible involvement in skeletal develop-ment J Biol Chem 276, 3628–3634
2 Scherer PE, Williams S, Fongliano M, Baldini G & Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes J Biol Chem
270, 26746–26749
3 Hu E, Liang P & Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity
J Biol Chem 271, 10697–10703
4 Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity Biochem Biophys Res Commun 257, 79–83
Trang 75 Kishore U, Gaboriaud C, Waters P, Shrive AK,
Green-hough TJ, Reid KBM, Sim RB & Arlaud GJ (2004)
C1q and tumor necrosis factor superfamily: modularity
and versatility Trends Immunol 25, 551–561
6 Wong GW, Wang J, Hug C, Tsao TS & Lodish HF
(2004) A family of Acrp30⁄ adiponectin structural and
functional paralogs Proc Natl Acad Sci USA 101,
10302–10307
7 Maeda T, Jikko A, Abe M, Yokohama-Tamaki T,
Akiyama H, Furukawa S, Takigawa M & Wakisaka S
(2006) Cartducin, a paralog of Acrp30⁄ adiponectin is
induced during chondrogenic differentiation and
pro-motes proliferation of chondrogenic precursors and
chondrocytes J Cell Physiol 206, 537–544
8 Hall BK & Miyake T (1995) Divide, accumulate,
differ-entiate: cell condensation in skeletal; development
revis-ited Int J Dev Biol 39, 881–893
9 Hill CS & Treisman R (1995) Transcriptional regulation
by extracellular signals: mechanisms and specificity Cell
80, 199–211
10 Seger R & Krebs EG (1995) The MAPK signaling
cas-cade FASEB J 9, 726–735
11 Lawlor MA & Alessi DR (2001) PKB⁄ Akt: a key
medi-ator of cell proliferation, survival and insulin responses?
J Cell Sci 114, 2903–2910
12 Kamiya N, Jikko A, Kimata K, Damsky C, Shimizu K
& Watanabe H (2002) Establishment of a novel
chon-drocytic cell line N1511 derived from p53-null mice
J Bone Miner Res 17, 1832–1842
13 Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo
T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda
M et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 423, 762– 769
14 O’Rear L, Longobardi L, Torello M, Law BK, Moses
HL, Chiarelli F & Spagnoli A (2005) Signaling cross-talk between IGF-binding protein-3 and transforming growth factor-(beta) in mesenchymal chondroprogenitor cell growth J Mol Endocrinol 34, 723–737
15 Datta SR, Brunet A & Greenberg ME (1999) Cellular survival: a play in three Akts Genes Dev 13, 2905–2927
16 Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shi-yanova T, Roninson I, Weng W, Suzuki R, Tobe K
et al.(2001) Growth retardation and increased apopto-sis in mice with homozygous disruption of the akt1 gene Genes Dev 15, 2203–2208
17 Gille H & Downward J (1999) Multiple Ras effector pathways contribute to G1 cell cycle progression J Biol Chem 274, 22033–22040
18 Jones SM & Kazlauskas A (2001) Growth-factor-depen-dent mitogenesis requires two distinct phases of signal-ing Nat Cell Biol 3, 165–172
19 Nakamura Y, Esnault S, Maeda T, Kelly EAB, Malter
JS & Jarjour NN (2004) Ets-1 regulates TNF-a-induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts J Immunol 172, 1945– 1952